RET/PTC1/3 AND BRAF W T/MUT mRNA E XPRESSION IN TUMORS OF THE HUMAN THYROID

Authors

  • Guda B. B. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • Pushkarev V. M. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • Zhuravel O. V. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • Kovalenko A. Ye. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • Tarachenko Y. M. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine
  • Tronko M. D. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2017.2.05

Keywords:

: human thyroid, highly differentiated malignant tumors, rearrangements RET/PTC, mutations and expression of BRAF.

Abstract

There were studied the chromosomal translocation of receptor tyrosine kinase gene RET/PTC1, RET/PTC3,
gene mutations of protein kinase B-RAF (BRAFV600E) and the expression of BRAFwt in the multinodular
goiter tissue, follicular and papillary carcinoma of the human thyroid. Of the 29 tissue samples which were
studied, changes in the expression, gene mutations and rearrangements were detected in 11 cases (38 %). In one
tumor sample of papillary carcinoma double rearrangement of the gene RET — RET/PTC1 and RET/PTC3 was
found. In a more aggressive invasive tumors the expression level RET/PTC1 and RET/PTC3 was higher than
in encapsulated tumors. It was observed the increased expression of protein kinase BRAF (BRAFwt) in some
samples of tumor tissue of follicular carcinoma and multinodular goiter.
The significance of MAPK signaling pathway in tumors of the thyroid was discussed.

References

Kumar A, Rajendran V, Sethumadhavan R, Purohit R. Sci World J 2013; 2013(756134):1-6. doi: 10.1155/2013/756134.

Beeram M, Patnaik A, Rowinsky EK. J Clin Oncol 2005; 23:6771-6790. https://doi.org/10.1200/JCO.2005.08.036

Guda BB, Pushkar’ov VV, Zhuravel’ OV, et al. Dopovidi NAN Ukrai’ny 2015; 10:93-97. https://doi.org/10.15407/dopovidi2015.10.093

Guda BB, Pushkarev VM, Pushkarev VV, et al. J Endocrinol Metab 2015; 1 (1002):1-5.

Caronia LM, Phay JE, Shah MH. Clin Cancer Res 2011; 17(24):7511-7517. https://doi.org/10.1158/1078-0432.CCR-11-1155

McCubrey JA, Steelman LS, Chappell WH, et al. Biochim Biophys Acta 2007; 1773(8):1263-1284. https://doi.org/10.1016/j.bbamcr.2006.10.001

Voskobojnyk LG. Zhurn AMN Ukrai’ny 2010; 16(4):605-629.

Xing M. Nat Rev Cancer 2013; 13:184-199. https://doi.org/10.1038/nrc3431

Montagut C, Settleman J. Cancer Lett 2009; 283(2):125-134. https://doi.org/10.1016/j.canlet.2009.01.022

Milosevic Z, Pesic M, Stankovic T, et al. Transl Res 2014; 164(5):411-423. https://doi.org/10.1016/J.trsi.2014.06.005

Livak KJ, Schmittgen TD. Methods 2001; 25:402-408. https://doi.org/10.1006/meth.2001.1262

Nakazawa T, Kondo T, Kobayashi Y, et al. Cancer 2005; 104(5):943-951. https://doi.org/10.1002/сncr.21270

Park JI. Front Biol (Beijing) 2014; 9(2):95-103. https://doi.org/10.1007/s11515-014-1299-x

Park JI, Strock CJ, Ball DW, Nelkin BD. Mol Cell Biol 2003; 23(2):543-554. https://doi.org/10.1128/MCB.23.2.543-554.2003

Wu PK, Hong SK, Veeranki S, et al. Mol Cell Biol 2013; 33(20):4051-4067. https://doi.org/10.1128/MCB.00021-13

Downloads

Published

2021-08-18

How to Cite

Guda, B. B., Pushkarev, V. M., Zhuravel, O. V., Kovalenko, A. Y., Tarachenko, Y. M., & Tronko, M. D. (2021). RET/PTC1/3 AND BRAF W T/MUT mRNA E XPRESSION IN TUMORS OF THE HUMAN THYROID. Problems of Endocrine Pathology, 60(2), 31-37. https://doi.org/10.21856/j-PEP.2017.2.05

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)